Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. FDX
4. CBRS
5. HTZ
6. USO
7. SPY
8. LAES
9. KBH
10. HON

Go back to Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies

October 4, 2021 11:23 AM EDT

Jefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.

... More

Xenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel

October 4, 2021 10:39 AM EDT

Stifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More